An observational study in Hemophilia, sponsored by Investigación en Hemofilia y Fisioterapia. Not yet recruiting at 1 site in Spain. Open to male participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by Investigación en Hemofilia y Fisioterapia · Observational
Introduction: Prophylaxis with emicizumab has substantially improved hemorrhagic control in hemophilia A. However, the longitudinal incidence of ultrasonographically detected articular damage in initially healthy joints remains insufficiently characterized.
Objective: To estimate the incidence of ultrasonographically detected articular damage in initially healthy joints among patients with hemophilia A receiving prophylaxis with emicizumab and to explore its association with relevant clinical variables.
Methods: A prospective, longitudinal, observational study will be conducted in approximately 70 patients with hemophilia A receiving emicizumab, with an estimated recruitment of approximately 270 initially healthy joints. The study is purely observational and does not involve evaluation of the investigational product nor modification of the therapeutic regimen; dosing, administration intervals, and all clinical decisions regarding emicizumab will be determined exclusively at the discretion of the treating hematologist. Assessments will be performed at baseline and at 12 and 24 months. The unit of analysis will be the joint, including elbows, knees, and ankles without ultrasonographic evidence of articular damage and without a history of clinically evident hemarthrosis at study entry.
The primary endpoint will be the occurrence of incident ultrasonographically detected articular damage, assessed using the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) protocol. Secondary outcomes will include clinical joint health assessed by the Hemophilia Joint Health Score (HJHS), version 2.1; the frequency of joint hemarthroses measured by the annualized joint bleeding rate (AJBR); and habitual physical activity levels evaluated through age-specific validated questionnaires. Statistical analyses will account for intra-patient correlation among joints.
Expected Results: A low to moderate incidence of ultrasonographically detected articular damage in initially healthy joints is anticipated during follow-up, providing clinically relevant information regarding structural joint preservation in patients with hemophilia A receiving emicizumab prophylaxis.
866 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.
This study's planned enrollment of 70 is below the median of 80 across 314 observational studies indexed under Hemophilia A.
Browse Hemophilia A studies →Investigación en Hemofilia y Fisioterapia is the lead sponsor of 54 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with hemophilia A receiving prophylactic treatment with emicizumab
Exclusion Criteria:
Patients with hemophilia A receiving prophylactic treatment with emicizumab
Other: Hemophilia patients
A prospective, longitudinal, observational study will be conducted in patients with hemophilia A receiving prophylaxis with emicizumab, with a 24-month follow-up period. Three assessments will be performed: at baseline, 12 months, and 24 months.
Measurement of Ultrasonographically Detected Articular Damage in Elbows, Knees, and Ankles
Ultrasonographically detected articular damage will be assessed using the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) protocol through standardized musculoskeletal ultrasound examination. This scoring system evaluates three structural domains per joint: synovial (hypertrophy and effusion), cartilage, and bone. Each joint is assigned an ordinal score ranging from 0 (no abnormalities) to a maximum of 8 points, derived from the combined assessment of the synovial, cartilaginous, and osseous domains. The HEAD-US protocol enables detection of subclinical joint damage and early structural changes, even in the absence of clinically evident hemarthrosis.Scree
Time frame: Baseline visit, at 12 months, and at 24 months.
Measurement of Clinical Joint Health in Knees, Ankles, and Elbows
Clinical joint health will be assessed using the Hemophilia Joint Health Score, version 2.1 (HJHS 2.1). This instrument evaluates eight items per joint: swelling (edema), duration of swelling, pain, muscle atrophy, crepitus, strength deficit, loss of range of motion, and joint deformity. Additionally, it includes a global gait assessment scored from 0 to 4. Each item is rated on an ordinal scale according to the instrument's predefined criteria, yielding a per-joint score ranging from 0 to 20 and a total score ranging from 0 to 124. Higher scores indicate worse clinical joint health.
Time frame: Baseline visit, at 12 months, and at 24 months.
Measurement of Joint Hemorrhagic Phenotype
This variable will be assessed using the Annualized Joint Bleeding Rate (AJBR), calculated as the number of hemarthroses occurring during the observation period divided by the total days of follow-up and multiplied by 365.25. The AJBR will be calculated both globally and on a per-joint basis, based on systematically recorded bleeding events obtained through structured clinical interviews.
Time frame: Baseline visit, at 12 months, and at 24 months.
Measurement of Physical Activity Level in patients under 18 years of age
This variable will be assessed using the Physical Activity Questionnaire for Adolescents (PAQ-A). The PAQ-A consists of nine items evaluating participation in various types of physical and sports activities; frequency of activity during physical education classes; activity during recess and leisure time; after-school activity; weekend activity; and overall level of habitual physical activity. Each item is scored on a 5-point Likert scale (1 to 5), and the final score corresponds to the mean of all items. Higher scores indicate a greater level of habitual physical activity.
Time frame: Baseline visit, at 12 months, and at 24 months.
Measurement of Physical Activity Level in Adult Patients
This variable will be assessed using the International Physical Activity Questionnaire - Long Form (IPAQ-LF). The IPAQ-LF captures physical activity across four domains: work-related physical activity, active transportation, domestic and household activities, and leisure-time physical activity. Within each domain, the time spent in vigorous-intensity activity, moderate-intensity activity, and walking is recorded, allowing for the calculation of total energy expenditure expressed in MET-minutes per week (MET-min/week).
Time frame: Baseline visit, at 12 months, and at 24 months.
Measurement of Treatment Adherence
This variable will be assessed using the Torres questionnaire for treatment adherence in hemophilia. This hemophilia-specific instrument evaluates five dimensions: disease awareness, perceived sequelae, treatment-related difficulties, physician-patient relationship, and hemorrhagic processes. Higher scores indicate greater adherence within the corresponding domain.
Time frame: Baseline visit, at 12 months, and at 24 months.
Measurement of Age
This variable, used to describe the sample and control for potential confounding factors, will be measured as a quantitative variable (in years)
Time frame: Screening visit
Measurement of Hemophilia Severity
This variable, used to describe the sample and control for potential confounding factors, will be measured as an ordinal variable (severe / moderate / mild).
Time frame: Screening visit
Measurement of Inhibitor Status
This variable, used to describe the sample and control for potential confounding factors, will be measured as a dichotomous variable (yes / no)
Time frame: Screening visit
Measurement of Duration of Emicizumab Prophylaxis
This variable, used to describe the sample and control for potential confounding factors, will be measured as a quantitative variable (in years).
Time frame: Screening visit
Plan to share: Undecided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Investigación en Hemofilia y Fisioterapia